Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals to Showcase SAR-bisPSMA Prostate Cancer Data at EANM Conference
Clarity Pharma 64Cu/67Cu SAR-bisPSMA data accepted for EANM, featuring oral presentation and a 700–800-patient dataset that could reshape prostate cancer care.
Clarity Pharma Secures Key Supply Deal to Boost Commercialisation of Prostate Cancer Agent
Clarity Pharmaceuticals inks Theragenics Cu-64 deal to scale US manufacturing for 64Cu-SAR-bisPSMA ahead of FDA NDA, boosting commercialization.
Clarity Pharmaceuticals signs copper-64 isotope supply deal for use in prostate cancer trials
Clarity Pharmaceuticals (ASX: CU6) has signed a deal with the Australian Institute for Bioengineering and Nanotechnology (AIBN), located within the University of Queensland, for the supply of the copper-64 (cu-64) isotope used in the manufacture of diagnostic 64Cu-SAR-bisPSMA. Clarity will use the isotope to support the Phase III Clarify and Amplify registrational trials, an ongoing […]
Clarity Pharmaceuticals gains FDA fast-track status for advanced prostate cancer imaging drug
Oncology specialist Clarity Pharmaceuticals (ASX: CU6) has been granted fast-track designation by the US Food and Drug Administration (FDA) for the use of its 64Cu-SAR-bisPSMA in positron emission tomography imaging for prostate cancer. SAR-bisPSMA – a next-generation theranostic radiopharmaceutical with dual prostate-specific membrane antigen (PSMA)-targeting agents linked to Clarity’s SAR chelator technology – utilises copper […]